Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder.
Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder.
复制标题
广泛性焦虑症患者使用文拉法辛后出现抗精神病药物恶性综合征。
DOI：
10.1016/s0929-6646(09)60115-7
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Wenjiang Chen
中科院分区：
文献类型：
--
作者：
Tsung;Pei;Chi;K. Tsai;Wenjiang Chen
神经阻滞剂恶性综合征（NMS）是一种潜在的致死性神经阻滞剂不良反应，其特征是高热、锥体外系症状、意识改变和自主神经功能障碍。虽然NMS最常由高效的神经阻滞剂引起，但其发展也与阻断中枢多巴胺通路的非神经阻滞剂的使用有关。68岁男性，患有广泛性焦虑障碍和抑郁症状，在急诊科（ED）出现高烧、震颤、肌肉僵硬、横纹肌溶解和精神状态改变。NMS被认为是由于最近增加文拉法辛（一种5 -羟色胺去甲肾上腺素再摄取抑制剂）的治疗方案并随后增加剂量引起的。他在急诊科和重症监护室成功地接受了溴隐亭、劳拉西泮和补液治疗。
Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse reaction to neuroleptics, which is characterized by hyperthermia, extrapyramidal symptoms, altered consciousness and autonomic dysfunction. Although NMS is most commonly induced by the high-potency neuroleptics, its development has also been associated with the use of non-neuroleptic agents that block central dopamine pathways. A 68-year-old man with generalized anxiety disorder and depressive symptoms presented at the emergency department (ED) with high fever, tremor, muscle rigidity, rhabdomyolysis and altered mental status. NMS was considered to have been caused by the recent addition and subsequent dose increase in his treatment regimen of venlafaxine, a serotonin norepinephrine reuptake inhibitor. He was successfully treated with bromocriptine, lorazepam, and fluid hydration in the ED and intensive care unit.